150375-75-0|Relcovaptan|(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide|-范德生物科技公司

Relcovaptan

NMR下载 COA and HPLC MSDS下载
names：
(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide
CAS号：
150375-75-0
MDL Number：
MF(分子式)： C28H27Cl2N3O7S MW(分子量)： 620.49
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK18537-5mg	5mg	>98%	¥ 4200.00	¥ 4200.00		2 Weeks	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide
英文别名	Relcovaptan; SR-49059; SR 49059; SR49059;
CAS号	150375-75-0
Inchi	InChI=1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1
InchiKey	CEBYCSRFKCEUSW-NAYZPBBASA-N
分子式 Formula	C28H27Cl2N3O7S
分子量 Molecular Weight	620.49
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Relcovaptan(CAS:150375-75-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Relcovaptan is a selective non-peptide vasopressin V1A receptor antagonist.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Kubo A, Shinoda M, Katagiri A, Takeda M, Suzuki T, Asaka J, Yeomans DC, Iwata K. Oxytocin alleviates orofacial mechanical hypersensitivity associated with infraorbital nerve injury through vasopressin-1A receptors of the rat trigeminal ganglia. Pain. 2017 Apr;158(4):649-659. doi: 10.1097/j.pain.0000000000000808. PubMed PMID: 28072605.

[2]Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V(1A) receptors. Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E127-E135. doi: 10.1152/ajpendo.00269.2016. Epub 2016 Dec 20. PubMed PMID: 27998960.

[3] Cragg B, Ji G, Neugebauer V. Differential contributions of vasopressin V1A and oxytocin receptors in the amygdala to pain-related behaviors in rats. Mol Pain. 2016 Nov 11;12. pii: 1744806916676491. Print 2016. PubMed PMID: 27837170; PubMed Central PMCID: PMC5117246.

[4] Hicks C, Ramos L, Dampney B, Baracz SJ, McGregor IS, Hunt GE. Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059. Brain Res Bull. 2016 Oct;127:208-218. doi: 10.1016/j.brainresbull.2016.10.005. Epub 2016 Oct 8. PubMed PMID: 27725169.

[5] Ramos L, Hicks C, Caminer A, Couto K, Narlawar R, Kassiou M, McGregor IS. MDMA ('Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacol Biochem Behav. 2016 Nov - Dec;150-15[5]115-123. doi: 10.1016/j.pbb.2016.10.002. Epub 2016 Oct 7. PubMed PMID: 27725273.

6: Javadian N, Rahimi N, Javadi-Paydar M, Doustimotlagh AH, Dehpour AR. The modulatory effect of nitric oxide in pro- and anti-convulsive effects of vasopressin in PTZ-induced seizures threshold in mice. Epilepsy Res. 2016 Oct;12

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开